VEGFA and gastric cancer: The anti-angiogenic drugs employed in gastric cancer clinical trials mainly target VEGFA such as the monoclonal humanized antibody bevacizumab, or the VEGFR2, in particular ramucirumab and selective tyrosine kinase inhibitors such as sunitinib, sorafenib and apatinib.